Trends and Risk Factors for Venous Thromboembolism Among Hospitalized Medical Patients.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 11 2022
Historique:
entrez: 21 11 2022
pubmed: 22 11 2022
medline: 24 11 2022
Statut: epublish

Résumé

While hospital-associated venous thromboembolism (HA-VTE) is a known complication of hospitalization, contemporary incidence and outcomes data are scarce and methodologically contested. To define and validate an automated electronic health record (EHR)-based algorithm for retrospective detection of HA-VTE and examine contemporary HA-VTE incidence, previously reported risk factors, and outcomes. This cohort study was conducted using hospital admissions between January 1, 2013, and June 30, 2021, with follow-up until December 31, 2021. All medical (non-intensive care unit) admissions at an integrated health care delivery system with 21 hospitals in Northern California during the study period were included. Data were analyzed from January to June 2022. Previously reported risk factors associated with HA-VTE and administration of pharmacological prophylaxis were evaluated as factors associated with HA-VTE. Yearly incidence rates and timing of HA-VTE events overall and by subtype (deep vein thrombosis, pulmonary embolism, both, or unknown), as well as readmissions and mortality rates. Among 1 112 014 hospitalizations involving 529 492 patients (268 797 [50.8%] women; 75 238 Asian [14.2%], 52 697 Black [10.0%], 79 398 Hispanic [15.0%], and 307 439 non-Hispanic White [58.1%]; median [IQR] age, 67.0 [54.0-79.0] years), there were 13 843 HA-VTE events (1.2% of admissions) occurring in 10 410 patients (2.0%). HA-VTE events increased from 307 of 29 095 hospitalizations (1.1%) in the first quarter of 2013 to 551 of 33 729 hospitalizations (1.6%) in the first quarter of 2021. Among all HA-VTE events, 10 746 events (77.6%) were first noted after discharge. In multivariable analyses, several factors were associated with increased odds of HA-VTE, including active cancer (adjusted odds ratio [aOR], 1.96; 95% CI, 1.85-2.08), prior VTE (aOR, 1.71; 95% CI, 1.63-1.79), and reduced mobility (aOR, 1.63; 95% CI, 1.50-1.77). Factors associated with decreased likelihood of HA-VTE included Asian race (vs non-Hispanic White: aOR, 0.65; 95% CI, 0.61-0.69), current admission for suspected stroke (aOR, 0.73; 95% CI, 0.65-0.81), and Hispanic ethnicity (vs non-Hispanic White: aOR, 0.81; 95% CI, 0.77-0.86). HA-VTE events were associated with increased risk of readmission (hazard ratio [HR], 3.33; 95% CI, 3.25-3.41) and mortality (HR, 1.63; 95% CI, 1.57-1.70). This study found that HA-VTE events occurred in 1.2% of medical admissions, increased over time, and were associated with increased adverse outcomes. These findings suggest that approaches designed to mitigate occurrence and outcomes associated with HA-VTE may remain needed.

Identifiants

pubmed: 36409498
pii: 2798830
doi: 10.1001/jamanetworkopen.2022.40373
pmc: PMC9679881
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2240373

Références

JAMA. 2009 May 6;301(17):1790-7
pubmed: 19417196
JAMA. 2013 Oct 9;310(14):1482-9
pubmed: 24100354
BMC Musculoskelet Disord. 2021 Jul 6;22(1):608
pubmed: 34229632
J Thromb Thrombolysis. 2022 May;53(4):766-776
pubmed: 35489004
Thromb Res. 2022 May;213:34-42
pubmed: 35279504
J Hosp Med. 2017 Apr;12(4):231-237
pubmed: 28411291
Thromb Res. 2015 Apr;135(4):636-42
pubmed: 25666908
Perm J. 2016 Fall;20(4):15-225
pubmed: 27548806
Semin Oncol. 2014 Jun;41(3):302-10
pubmed: 25023346
Lancet. 2010 Dec 11;376(9757):2032-9
pubmed: 21131039
Blood Adv. 2018 Nov 27;2(22):3198-3225
pubmed: 30482763
BMJ Qual Saf. 2014 Mar;23(3):187-95
pubmed: 23708438
Thromb J. 2019 Jan 25;17:2
pubmed: 30697126
Res Pract Thromb Haemost. 2022 Feb 15;6(2):e12666
pubmed: 35224417
Thromb Res. 2009;123 Suppl 4:S11-7
pubmed: 19303496
Am J Med. 2019 Dec;132(12):1450-1457.e1
pubmed: 31247183
Ann Med. 2018 Sep;50(6):529-537
pubmed: 30001640
Surgery. 2015 Mar;157(3):423-31
pubmed: 25633736
Med Care. 2008 Mar;46(3):232-9
pubmed: 18388836
Thromb Res. 2020 May;189:112-118
pubmed: 32199174
Arch Intern Med. 2002 Jun 10;162(11):1245-8
pubmed: 12038942
Thromb Haemost. 2022 Jul;122(7):1231-1238
pubmed: 34784645
Circulation. 2020 Jun 16;141(24):e914-e931
pubmed: 32375490
Chest. 2012 Feb;141(2 Suppl):e195S-e226S
pubmed: 22315261
J Thromb Haemost. 2010 Nov;8(11):2450-7
pubmed: 20738765
Curr Opin Anaesthesiol. 2018 Apr;31(2):215-218
pubmed: 29334497
MMWR Morb Mortal Wkly Rep. 2012 Jun 8;61(22):401-4
pubmed: 22672974
Am J Med. 2016 Sep;129(9):1001.e9-1001.e18
pubmed: 27107925
J Thromb Haemost. 2014 Oct;12(10):1580-90
pubmed: 25302663
J Thromb Haemost. 2005 Aug;3(8):1611-7
pubmed: 16102026
JAMA Cardiol. 2019 Feb 1;4(2):163-173
pubmed: 30649175
J Biomed Inform. 2021 Oct;122:103892
pubmed: 34454079
Intern Med J. 2018 Feb;48(2):157-165
pubmed: 29139173
Cureus. 2021 Mar 5;13(3):e13721
pubmed: 33833932
Arch Intern Med. 2010 Oct 25;170(19):1774-5
pubmed: 20975028
J Thromb Haemost. 2022 Jul;20(7):1645-1652
pubmed: 35426248
Mayo Clin Proc. 2001 Nov;76(11):1102-10
pubmed: 11702898
Diabet Med. 2021 May;38(5):e14452
pubmed: 33165941
Blood Coagul Fibrinolysis. 2015 Jun;26(4):368-72
pubmed: 25688463
BMJ Qual Saf. 2013 Oct;22(10):809-15
pubmed: 24048616
Med Care. 2017 Dec;55(12):e137-e143
pubmed: 29135777
JRSM Short Rep. 2013 Jul 30;4(9):2042533313489824
pubmed: 24040503
J Thromb Thrombolysis. 2016 Jan;41(1):3-14
pubmed: 26780736
JAMA Intern Med. 2014 Oct;174(10):1577-84
pubmed: 25133488
N Engl J Med. 2004 Jun 17;350(25):2558-63
pubmed: 15201412
BMJ Open. 2021 Jul 29;11(7):e045672
pubmed: 34326045

Auteurs

Elad Neeman (E)

Department of Hematology and Oncology, The Permanente Medical Group, San Rafael, California.

Vincent Liu (V)

Division of Research, Kaiser Permanente Northern California, Oakland.

Pranita Mishra (P)

Division of Research, Kaiser Permanente Northern California, Oakland.

Khanh K Thai (KK)

Division of Research, Kaiser Permanente Northern California, Oakland.

James Xu (J)

Internal Medicine Residency Program, Kaiser Permanente Northern California, San Francisco.

Heather A Clancy (HA)

Division of Research, Kaiser Permanente Northern California, Oakland.

David Schlessinger (D)

Division of Research, Kaiser Permanente Northern California, Oakland.

Raymond Liu (R)

Division of Research, Kaiser Permanente Northern California, Oakland.
Department of Hematology and Oncology, The Permanente Medical Group, San Francisco, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH